Stocks and Finance

Genentech

Genentech 5/1/2012

07:09 : Dako enters into collaboration with Genentech on the FDA regulatory submiss - GLOSTRUP, DENMARK--(Marketwire - May 1, 2012) - Dako, a worldwide provider of cancer diagnostics solutions, has signed an agreement with Genentech, member of the Roche Group, to collaborate on the regulatory submissions of ...
Source : marketwire-com

Genentech 3/27/2012

04:44 : Genmab says GSK settles patent case with Genentech - Danish biotech company Genmab said on Tuesday its partner GlaxoSmithKline had agreed a settlement with Roche-owned Genentech regarding two U.S. patents that relate to Genmab's ofatumumab antibody.
Source : ibtimes-com

Genentech 2/14/2012

17:15 : Counterfeit Avastin hits U.S. shores, Genentech warns - Counterfeit Avastin — the world’s best-selling cancer drug — is being distributed in the United States, Genentech Inc. and parent company Roche warned Tuesday. Officials from South San Francisco-based Genentech ...
Source : bizjournals-com

Genentech 11/9/2011

03:15 : FDA to review a Genentech skin-cancer treatment - TEL AVIV (MarketWatch) -- Roche Holding AG's Genentech subsidiary said on Wednesday that the U.S. Food and Drug Administration agreed to review vismodegib, a proposed treatment taken by mouth for adults who have advanced basal-cell ...
Source : marketwatch-com

Genentech 9/26/2011

04:51 : Genentech antibody-chemo punch strong in breast cancer trial - A mid-stage trial of a highly selective version of Genentech Inc.’s blockbuster cancer-fighting drug Herceptin found that metastatic breast cancer patients lived a median of five months longer without their disease worsening. ...
Source : bizjournals-com

Genentech 8/17/2011

10:16 : FDA approves Genentech skin-cancer treatment - Genentech Inc. said Wednesday that the U.S. Food and Drug Administration approved its treatment for metastatic melanoma. South San Francisco-based Genentech said Zelboraf is designed for patients with mutation-positive ...
Source : bizjournals-com

Genentech 8/8/2011

20:12 : Genentech to pay $28M in cancer drug deal with Array - Genentech will pay $28 million next month as a downpayment for Array BioPharma to develop two cancer drugs designed to disrupt a tumor cell’s natural repair mechanism. The deal centers on an oral drug developed by ...
Source : bizjournals-com

Genentech 7/8/2011

20:50 : Genentech patent may be key to cancer drug maker's IPO - One of the biggest biotech IPOs so far this year carries a significant Bay Area caveat and an important connection. Cancer drug developer Merrimack Pharmaceuticals Inc. of Cambridge, Mass., said late Friday that it plans to sell about $173 million of ...
Source : bizjournals-com

Genentech 6/26/2011

21:11 : Genentech to Appeal to F.D.A. for Breast Cancer Drug - Genentech will ask the F.D.A. to rethink its proposal to revoke the approval of Avastin for breast cancer on the grounds that new studies did not confirm that the drug helped patients.
Source : nytimes-com
actualidad Genentech -
Logo Genentech


Biotechnology

Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts